Interestingly, chimeric antigen receptor (CAR) T cells targeting CD123 ± CD33 are also being tested under phase 1 clinical trials in patients with high-risk hematologic malignancies including MDS (NCT04156256, NCT03795779), which is currently recruiting. This evidence concerns the gene CD33 and myelodysplastic syndrome.